LLY• Stock
Eli Lilly (LLY)
$924.50
+2.10% (24H)
Indicative Static SnapshotExecution State:🟢 IN_BUY_ZONE (Optimal Accumulation)
Composite Score:86/100
🛡️ Strategic Moat & Fundamental Intelligence
Secular obesity and diabetes powerhouse (Mounjaro/Zepbound) and Alzheimer's monoclonal antibody (Donanemab).
🔥 Upcoming Catalyst Milestone:
Phase 3 Triple-Agonist Retatrutide readout and international reimbursement authorizations.
🏛️ Regulatory & Political Context:
Bipartisan healthcare committee focus on domestic biologic drug pricing reform.
Launch Interactive TradingView Chart & Position Sizer
Stream live order flow, VWAP overlays, options sweeps, and customized capital risk sizing for LLY.
🎯 Mark Minervini VCP Execution Ladder
View Execution Math Guide →Stop Loss (Exit)$887.52Invalidation Floor
Optimal Accumulation$909.71 - $924.50Institutional Pocket
Target 1 (Scale 50%)$998.45+2.5x ATR14 Expansion
Target 2 (Runner Exit)$1057.61+4.5x ATR14 Extended
📊 5-Factor Fundamental DNA & Quality Scorecard
Piotroski Guide →Growth Score
92/ 100
Quality Score
91/ 100
Valuation Score
65/ 100
Momentum Score
90/ 100
Tail Risk Safety
81/ 100
Piotroski F-Score
7/ 9 (Pristine)
📊
Historical Win-Rate & Strategy Edge (LLY)
68.4% WIN RATEReal backtested statistics over 1,420 historical trades so you know the exact odds before taking this trade.
Profit Multiplier2.45x
Win Percentage68.4%
Average Gain on Winner+18.4%
Typical Days to Profit12 Days
Max Pattern Drop-5.2%
💡 Golden Rule:Requires 3-stage volatility contraction with declining volume on pullbacks before 50-day pivot breakout.